ETON Eton Pharmaceuticals Inc.

5.71
-0.25  -4%
Previous Close 5.96
Open 5.97
52 Week Low 4.8
52 Week High 10.3
Market Cap $139,938,487
Shares 24,507,616
Float 19,620,018
Enterprise Value $128,600,543
Volume 634,058
Av. Daily Volume 665,092
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Topiramate Oral Solution
Seizures/migraine
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
REZIPRES (ephedrine hydrochloride injection)
Injectable hospital product
Approved
Approved
FDA approval announced June 15, 2021.
Cysteine Inj (DS-300)
Nutritional deficiencies
CRL
CRL
CRL received October 2020 (announced November 12, 2020). Expects to respond in December 2020.
Biorphen (ET-202)
Injectable hospital product
Approved
Approved
FDA Approval announced October 22, 2019.
ET-105 (Lamotrigine for Oral Suspension)
Lennox-Gastaut syndrome, epilepsy
CRL
CRL
CRL issued March 17, 2020. Additional trial to be completed in the coming months.
Novothyrox (EM-100)
Allergic conjunctivitis
Approved
Approved
FDA approval announced September 25, 2020.
Zonisamide oral suspension - (ET-104)
Neurological indication
CRL
CRL
CRL announced May 28, 2021. Inspection of the third-party manufacturing facility was unable to occur due to travel restrictions.
Dehydrated alcohol injection (DS-100)
Methanol poisoning
CRL
CRL
CRL announced May 28, 2021.
Alkindi Sprinkle
Pediatric adrenal insufficiency (AI)
Approved
Approved
FDA approval announced September 29, 2020.

Latest News

    • Expands Eton's Adrenal Insufficiency Orphan Drug Portfolio
    • ZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocortisone
    • Proprietary ZENEO® Needleless Device is Covered by 24 U.S. Patents Extending as Far as 2037

    DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject's ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

    "The ZENEO autoinjector is a revolutionary delivery system, and this product…

    • Expands Eton's Adrenal Insufficiency Orphan Drug Portfolio
    • ZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocortisone
    • Proprietary ZENEO® Needleless Device is Covered by 24 U.S. Patents Extending as Far as 2037

    DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject's ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

    "The ZENEO autoinjector is a revolutionary delivery system, and this product is a terrific strategic fit with our current adrenal insufficiency business. Patients, advocacy groups, and physicians in the adrenal insufficiency community have repeatedly expressed to us the need for a hydrocortisone autoinjector, so we are excited to be partnering with Crossject to bring this product to patients in need," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

    Patrick Alexandre, CEO of Crossject, added: ‘‘We are proud to announce a sound commercial agreement for ZENEO® Hydrocortisone in the US and Canada with an American leader in adrenal insufficiency. ETON has successfully established strong relations with the patient communities and medical specialists that are its core focus. ZENEO® Hydrocortisone answers a medical need. This strong partnership will contribute to saving lives by bringing to patients and their families a modern autoinjection possibility.''

    "We are delighted about Eton Pharmaceuticals' plans to partner with Crossject to bring this incredibly needed product to patients in the U.S.", said Dina Matos, Executive Director of CARES Foundation, a leading North American advocacy foundation for patients with congenital adrenal hyperplasia, the most common presentation of adrenal insufficiencies in children. "The challenge for patients and caregivers facing an adrenal crisis is serious; an easy-to-use needleless autoinjector of hydrocortisone will be a game changer for our patients. We welcome this advancement."

    ZENEO® is a proprietary needleless device developed and manufactured by Crossject. The pre-filled, single-use device propels medication through the skin in less than a tenth of a second. The device's compact form factor, simple two-step administration, and needle-free technology make it an ideal delivery system for emergency medications that need to be administered in stressful situations by non-healthcare professionals. Crossject holds more than 400 global patents on the device, including 24 issued in the United States that extend as far as 2037, and has successfully completed bioequivalence and human factor studies with the ZENEO device using various medications.

    Crossject has developed a proprietary, room-temperature stable liquid formulation of hydrocortisone to be delivered via the ZENEO device. ZENEO hydrocortisone is expected to be the first and only hydrocortisone autoinjector available for patients that require a rescue dose of hydrocortisone. Currently, injectable hydrocortisone is only available in the United States in a lyophilized powder formulation that must be reconstituted and manually delivered via a traditional syringe.

    Eton expects to submit a New Drug Application for the product to the U.S. Food and Drug Administration in 2023 and plans to request Orphan Drug Designation. In the United States, it is estimated that approximately 100,000 patients currently suffer from adrenocortical insufficiency and are at risk for adrenal crisis.

    Under the terms of the agreement, Crossject will receive development and regulatory milestone payments from Eton of up to $5.0 million, commercial milestones of up to $6.0 million, and a 10% royalty on net sales of the product. Crossject will be responsible for the management and expense of development, clinical, and manufacturing activities. Eton will be responsible for all regulatory and commercial activities.

    About Adrenal Crisis

    Patients with adrenal insufficiency can go into adrenal crisis if their cortisol levels are too low. Adrenal crisis is typically caused by missed doses of maintenance hydrocortisone, trauma, surgery, illness, fever, or major psychological distress. Signs of adrenal crisis include hyperpigmentation, severe weakness, nausea, abdominal pain, and confusion. It is estimated that approximately 8% of adrenal insufficiency patients will report an adrenal crisis in any given year and more than 6% of cases result in death.

    About Crossject

    Crossject (OTC:CRJTF, TICKER:ALCJ, LEI: 969500W1VTFNL2D85A65))) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. The company's portfolio currently contains eight products in advanced stages of development, including 7 emergency treatments, 5 of which are intended for life-threatening situations. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.

    About Eton Pharmaceuticals

    Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®, and has six additional products that have been submitted to the FDA.

    Company Contact:

    David Krempa



    612-387-3740



    Primary Logo

    View Full Article Hide Full Article
  1. DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.

    "We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelling benefit to hospitals and reduce the need for hospitals to rely on unapproved compounded products," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "This innovative sulfite-free formulation has been successfully sold in Europe for years, and we…

    DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.

    "We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelling benefit to hospitals and reduce the need for hospitals to rely on unapproved compounded products," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "This innovative sulfite-free formulation has been successfully sold in Europe for years, and we are excited to make it available to U.S. patients shortly."

    About Eton Pharmaceuticals

    Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from four FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, Rezipres®, and Alaway® Preservative Free, and has five additional products that have been submitted to the FDA.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton's business strategy, Eton's plans to develop and commercialize its product candidates, the safety and efficacy of Eton's product candidates, Eton's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton's product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton's development programs and financial position are described in additional detail in Eton's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investor Contact:

    David Krempa



    612-387-3740



    Primary Logo

    View Full Article Hide Full Article
  2. DEER PARK, Ill., May 28, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) in response to the submission of its New Drug Application (NDA) for dehydrated alcohol injection for the treatment of methanol poisoning. The CRL indicated that the FDA has completed its review of the application and has determined that the application cannot be approved in its present form. A Pre-Approval Inspection (PAI) of the product's European contract manufacturer is pending due to what the company believes are COVID-related travel restrictions. The company believes all other FDA questions raised in the letter can be fully…

    DEER PARK, Ill., May 28, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) in response to the submission of its New Drug Application (NDA) for dehydrated alcohol injection for the treatment of methanol poisoning. The CRL indicated that the FDA has completed its review of the application and has determined that the application cannot be approved in its present form. A Pre-Approval Inspection (PAI) of the product's European contract manufacturer is pending due to what the company believes are COVID-related travel restrictions. The company believes all other FDA questions raised in the letter can be fully addressed in a response in the coming months.

    About Eton Pharmaceuticals

    Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®, and has six additional products that have been submitted to the FDA.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton's business strategy, Eton's plans to develop and commercialize its product candidates, the safety and efficacy of Eton's product candidates, Eton's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton's product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton's development programs and financial position are described in additional detail in Eton's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Company Contact:

    David Krempa



    612-387-3740

     



    Primary Logo

    View Full Article Hide Full Article
    • First quarter 2021 revenue of $11.9 million
    • First quarter 2021 operating earnings of $5.4 million; EPS of $0.19
    • Eton now has three commercial, revenue-generating products

    DEER PARK, Ill., May 13, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided an update on business progress.

    "We are proud to report record revenue and the first profitable quarter in Eton's history," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "We have begun seeing the results of the years of hard work developing our product candidates. We now have three approved…

    • First quarter 2021 revenue of $11.9 million
    • First quarter 2021 operating earnings of $5.4 million; EPS of $0.19
    • Eton now has three commercial, revenue-generating products

    DEER PARK, Ill., May 13, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided an update on business progress.

    "We are proud to report record revenue and the first profitable quarter in Eton's history," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "We have begun seeing the results of the years of hard work developing our product candidates. We now have three approved and revenue generating products, and we expect to have a number of additional products launched later this year as a result of the four upcoming PDUFA dates over the next three months," added Brynjelsen.

    Q1 Business Highlights

    First quarter revenue of $11.9 million and operating income of $5.4 million. Revenue included sales or royalties received on three commercial products plus payments related to the sale of Eton's neurology oral liquids products.

    Launch of Alaway Preservative Free. In February, Bausch Health launched Alaway Preservative Free in major U.S. retailers. Eton collected a $1.5 million launch milestone plus a royalty on the product's sales in the first quarter.

    Completed sale of neurology oral liquid products. Eton completed the sale of its neurology portfolio to Azurity Pharmaceuticals. Eton will receive milestone payments of up to $45 million, $9.5 million of which was received in the first quarter, and a single digit royalty on product sales.

    ALKINDI® SPRINKLE

    Eton remains focused on the commercial launch of ALKINDI SPRINKLE in the United States. The first quarter of 2021 was the first full quarter of the product's launch. The company's sales representatives have already engaged with more than 90% of their initial targets in the pediatric endocrinology community, and sales representatives have been met with a positive reception from physicians, nurses, and caretakers.

    Although Initial sales force communications have largely been virtual due to COVID-19 related restrictions, certain physicians' offices and hospitals have recently begun accepting in-person meetings. Given the expectation for higher conversion rates on in-person meetings, Eton has adopted a sales force strategy that focuses resources most heavily in states where in-person meetings are taking place, rather than the traditional regional allocation of territories. The new strategy will allow all sales representatives to focus on maximizing in-person meetings, even if their previously assigned geography comprises states that are not accepting in-person visits. Eton will continue to refine the resource allocation in the coming weeks and months as additional states begin accepting in-person visits.

    In April, Eton presented virtually at the Pediatric Endocrinology Nursing Society national conference and the Pediatric Endocrinology Society annual meeting, the first two conferences since the product's launch.

    The company has seen strong adoption of ALKINDI SPRINKLE, and prescriptions continue to grow month over month. Over 100 new patient prescriptions have been written this year, and the company continues to work towards its goal of more than 400 new patient prescriptions by the end of the year.

    Pipeline Update

    Eton owns or has economic interests in six pipeline products that are currently under review with the FDA, four of which have been assigned Prescription Drug User Fee Act (PDUFA) dates:

    • May 27: Dehydrated Alcohol Injection
    • May 29: Zonisamide Oral Suspension
    • June 18: Ready-to-Use Ephedrine Injection
    • August 6: Topiramate Oral Solution

    Eton expects these products to be approved and launched later this year. In addition, given the company's strong financial position, it remains actively pursuing business development opportunities to add high-value late-stage orphan product candidates to its portfolio.

    Current Product Portfolio & Pipeline
    ProductStatus
    ALKINDI® SPRINKLECommercial
    Alaway® Preservative FreeCommercial
    Biorphen®Commercial
    Dehydrated Alcohol InjectionFiled
    Zonisamide Oral SuspensionFiled
    Topiramate Oral SolutionFiled
    Lamotrigine for SuspensionFiled
    RTU Ephedrine InjectionFiled
    Cysteine InjectionFiled
    ALKINDI® SPRINKLE - CanadaPre-Filing



    Financial Results

    Revenue: Eton reported revenue of $11.9 million for the first quarter of 2021, which included $9.5 million from the sale of its neurology oral liquid products and a $1.5 million milestone payment from Bausch Health for the launch of Alaway Preservative Free. In the prior-year period, the company reported revenue of $0.1 million.

    General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2021 were $4.1 million compared to $2.6 million in the prior-year period. The increase was largely due to increased costs related to the commercialization of ALKINDI SPRINKLE. G&A expenses for the first quarter of 2021 included $0.7 million of non-cash expenses.

    Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2021 were $0.9 million compared to $6.3 million in the prior-year period. The prior-year period included $4.8 million of one-time licensing payments for the acquisition of marketing rights to ALKINDI SPRINKLE. Absent any new business development transaction, the company expects full year 2021 R&D expenses to be substantially below 2020 levels.

    Net Income: Eton reported net income of $5.1 million for the first quarter of 2021, compared to a net loss of $9.0 million in the prior-year period. Eton reported diluted earnings per share (EPS) of $0.19 in the first quarter of 2021, compared to a loss of $0.50 per share in the prior year period.

    Cash Position: Eton reported cash and cash equivalents of $25.1 million as of March 31, 2021.

    Conference Call and Webcast Information:

    Eton Pharmaceuticals will host a conference call and webcast today at 4:30 p.m. ET (3:30 p.m. CT). To access the conference call, please dial 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 5847989. The webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at https://ir.etonpharma.com. The webcast will be archived and made available for replay on the company's website approximately two hours after the call and will be available for 30 days.

    About Eton Pharmaceuticals

    Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway® Preservative Free, and has six additional products that have been submitted to the FDA.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton's business strategy, Eton's plans to develop and commercialize its product candidates, the safety and efficacy of Eton's product candidates, Eton's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton's product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton's development programs and financial position are described in additional detail in Eton's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.



    Eton Pharmaceuticals, Inc.
    Condensed Statements of Operations
    (In thousands, except per share amounts)
    (Unaudited)
     
      For the three months ended
      March 31,  March 31,
      2021  2020
    Revenues:     
    Licensing revenue $11,500  $ 
    Product sales and royalties  397   99 
      Total net revenues  11,897   99 
            
    Cost of sales       
    Licensing revenue  1,500    
    Product sales and royalties  90   102 
    Total cost of sales  1,590   102 
            
    Gross profit (loss)  10,307   (3)
            
    Operating expenses:       
    Research and development  886   6,268 
    General and administrative  4,058   2,610 
    Total operating expenses  4,944   8,878 
            
    Income (loss) from operations  5,363   (8,881)
            
    Other expense:       
    Interest and other expense, net  (247)  (168)
            
    Income (loss) before income tax expense  5,116   (9,049)
            
    Income tax expense      
            
    Net income (loss) $5,116  $(9,049)
    Net income (loss) per share, basic  $0.21  $(0.50)
    Net income (loss) per share, diluted $0.19  $(0.50)
    Weighted average number of common shares outstanding, basic  24,453   18,143 
    Weighted average number of common shares outstanding, diluted  26,547   18,143 





    Eton Pharmaceuticals, Inc.

    Condensed Balance Sheets

    (in thousands, except share and per share amounts)

     
      March 31, 2021  December 31, 2020 
      (Unaudited)    
    Assets        
    Current assets:        
    Cash and cash equivalents $25,113  $21,295 
    Accounts receivable, net  300   48 
    Inventories  1,348   1,242 
    Equipment held-for-sale  551    
    Prepaid expenses and other current assets  2,962   2,116 
    Total current assets  30,274   24,701 
             
    Property and equipment, net  176   811 
    Intangible assets, net  537   575 
    Operating lease right-of-use assets, net  163   192 
    Other long-term assets, net  36   40 
    Total assets $31,186  $26,319 
             
    Liabilities and stockholders' equity        
    Current liabilities:        
    Accounts payable $1,761  $2,344 
    Current portion of long-term debt  385    
    PPP loan, current portion  341   280 
    Accrued liabilities  712   1,170 
    Total current liabilities  3,199   3,794 
             
    Long-term debt, net of discount and including accrued fees  6,183   6,532 
    Long-term portion of PPP and EIDL loans  170   231 
    Operating lease liabilities, net of current portion  79   99 
             
    Total liabilities  9,631   10,656 
             
    Commitments and contingencies        
             
    Stockholders' equity        
    Common stock, $0.001 par value; 50,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 24,482,616 and 24,312,808 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively  24   24 
    Additional paid-in capital  108,573   107,797 
    Accumulated deficit  (87,042)  (92,158)
    Total stockholders' equity  21,555   15,663 
             
    Total liabilities and stockholders' equity $                        31,186  $                        26,319 





    Eton Pharmaceuticals, Inc.
    Condensed Statements of Cash Flows
    (In thousands)
    (Unaudited)
     
      Three months ended

    March 31, 2021
     
     Three months ended

    March 31, 2020
    Cash flows from operating activities        
    Net income (loss) $5,116  $(9,049)
             
    Adjustments to reconcile net loss to net cash provided by (used in) operating activities:        
    Stock-based compensation  673   365 
    Common stock issued for product candidate licensing rights     1,264 
    Depreciation and amortization  155   162 
    Debt discount amortization  36   27 
    Changes in operating assets and liabilities:        
    Accounts receivable  (252)  268 
    Inventories  (106)  (1,346
    Prepaid expenses and other assets  (846  1,020 
    Accounts payable  (583)  608 
    Accrued liabilities  (478)  (536)
    Net cash provided by (used in) operating activities  3,715   (7,217)
             
    Cash used in investing activities        
    Purchases of property and equipment     (4)
             
    Cash flows from financing activities        
    Proceeds from sales of common stock, net of offering costs     7,459 
    Proceeds from employee stock option exercises  103   31 
    Net cash provided by financing activities  103   7,490 
             
    Change in cash and cash equivalents  3,818   269 
    Cash and cash equivalents at beginning of period  21,295   12,066 
    Cash and cash equivalents at end of period $25,113  $12,335 
             
    Supplemental disclosures of cash flow information        
    Cash paid for interest $214  $189 
    Cash paid for income taxes $  $ 
             

    Investor Contact:

    David Krempa



    612-387-3740

     



    Primary Logo

    View Full Article Hide Full Article
  3. DEER PARK, Ill., May 04, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2021 financial and operating results on Thursday, May 13, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).

    The live webcast can be accessed on the investors section of Eton's website at https://ir.etonpharma.com/. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 5847989. An archived webcast will be available…

    DEER PARK, Ill., May 04, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2021 financial and operating results on Thursday, May 13, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).

    The live webcast can be accessed on the investors section of Eton's website at https://ir.etonpharma.com/. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 5847989. An archived webcast will be available on Eton's website approximately two hours after the completion of the event and for 30 days thereafter.

    About Eton Pharmaceuticals

    Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway® Preservative Free, and has six additional products that have been submitted to the FDA.

    Investor Contact:

    David Krempa



    612-387-3740



    Primary Logo

    View Full Article Hide Full Article
View All Eton Pharmaceuticals Inc. News